ArticlebioRxiv : the preprint server for biology2026
Antiphage defence systems Druantia III and Zorya II synergise via shared DNA intermediates in a phage-specific manner.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Most bacteria encode multiple antiphage defence systems, but how these systems interact, remains poorly understood. Here, we define the mechanism of Druantia III and explore its synergy with Zorya II. Druantia III is a late-acting defence where DruH is the likely infection sensor and DruE is a helicase-nuclease effector that engages ssDNA-containing replication intermediates. Druantia III and Zorya II are each sensitive to the loss of RecD, whereas their synergy requires an intact RecBCD complex, indicating that the combined response depends on a shared DNA-processing hub. During T3 infection, Zorya apparently preserves this hub by limiting accumulation of the phage RecBCD-inhibitor Gp5.9, whereas DruE together with RecBCD promote the formation of DNA structures permissive for ZorE cleavage. During Bas37 infection, Druantia provides the dominant pathway and recruits ZorE in a non-canonical, ZorAB-independent manner. These findings show how shared DNA intermediates can connect defence systems into a coordinated antiphage response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.